Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06232564 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs

Study acronym: PELICAN
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Mar 2, 2028 to Oct 15, 2027 · Completion date: Aug 2, 2028 to Oct 15, 2027 · Site details revisedv4 Show 3 more changesShow less
    • Primary completion date: Mar 2, 2028 to Oct 15, 2027
    • Completion date: Aug 2, 2028 to Oct 15, 2027
    • Site details revised
  2. Eligibility criteria shortened, about 2 wordsv3 See this version in full on ClinicalTrials.gov ↗
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 2, 2024 to Jul 8, 2024 · Study sites: 0 to 1v2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 2, 2024 to Jul 8, 2024
    • Study sites: 0 to 1
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open label, single arm, phase II multicentre study designed to evaluate the efficacy and safety of pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy in patients with HG-NETs who are chemotherapy-naïve for their metastatic disease. The study will be conducted in up to 10 sites and will recruit up to a maximum of 20 evaluable participants.
Trial Details
NCT Number NCT06232564
Lead Sponsor Imperial College London
Conditions Neuroendocrine Tumors
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov